Tech Center 1600 • Art Units: 1623 1625 1654
This examiner grants 66% of resolved cases
Ernesto Valle serves in Tech Center 1600 and Art Unit 1623, having completed 38 resolved cases. His allowance rate is 65.8%, which indicates a moderate likelihood of success for applications on his docket. This 65.8% rate provides a clear expectation for practitioners navigating the complexities of this specific art unit. The 38 cases resolved by this examiner offer a consistent look at his typical prosecution outcomes.
The median days to allowance for this examiner is 1260, reflecting a relatively long duration for the patent process. However, the data shows an interview lift of 32.9%, which provides a substantial boost to the probability of success. This positive lift suggests that direct communication can be a very effective tool for resolving outstanding issues. The 1260-day median pendency is an important figure for practitioners to communicate to their clients when setting expectations.
Strategically, the 32.9% interview lift should be considered a primary option for overcoming rejections in Art Unit 1623. While the 65.8% allowance rate shows that success is achievable, the 1260-day median suggests that the process requires steady advocacy. With 38 cases resolved, the examiner's tendencies are becoming clearer, allowing for more informed planning. Applicants should utilize interviews to supplement written responses and potentially improve the odds of a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18706306 | PRODRUGS OF AXITINIB | Non-Final OA | OCULAR THERAPEUTIX, INC. |
| 17789019 | TARGETING THE INTRINSIC APOPTOTIC MACHINERY IN GLIOBLASTOMA | Final Rejection | The Regents of The University Of California |
| 17769454 | METHODS OF TREATING OR PREVENTING CACHEXIA | Non-Final OA | Toray Industries, Inc. |
| 18569581 | IMPROVED TREATMENT METHODS FOR CABAZITAXEL | Non-Final OA | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED |
| 18455978 | Substituted Pyrrolotriazines | Non-Final OA | Molecure S.A. |
| 17924103 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | Non-Final OA | DURECT CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy